CN117205266A - A pharmaceutical composition for reducing the harm of ionizing radiation - Google Patents

Abstract

The invention relates to a pharmaceutical composition for reducing the harm of ionizing radiation, and belongs to the technical field of traditional Chinese medicine. It is composed of the following ingredients by weight: 570-630 parts of Rehmannia glutinosa, 4-14 parts of Crystal Cyanoside, 17-27 parts of Nicetose, 60-80 parts of Ophiopogon japonicus polysaccharide, 75-95 parts of Poria polysaccharide, and 1-5 parts of Poria acid. 1-3 parts of Schisandrin. The pharmaceutical composition of the present invention has the advantage that it can promote the increase in the number of peripheral blood leukocytes of mice injured by ionizing radiation, reduce the number of micronuclei in bone marrow cells, help the body repair the damage caused by ionizing radiation, and has the effect of reducing the harm of ionizing radiation. effect.

Description

A pharmaceutical composition for reducing the harm of ionizing radiation

Technical field

The invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a pharmaceutical composition for reducing the harm of ionizing radiation.

Background technique

Ionizing radiation refers to radiation that carries enough energy to ionize atoms or molecules of matter, including cosmic rays, X-rays and radiation from radioactive materials. There are two main sources of ionizing radiation: one is natural radiation, which comes from the air and water on the universe and the earth's surface, as well as radioactive substances in the human body; the other is artificial radiation, including photoradiology, medical imaging and radiotherapy in the medical field. Damage to the body's entire body or local tissues caused by exposure to ionizing radiation is called ionizing radiation injury. The main source of ionizing radiation damage is radiotherapy for malignant tumors. When radiation kills tumor cells, it will also cause certain damage to surrounding normal tissues, causing radiation damage to multiple systems of the body. The most common of these is Damage to the hematopoietic system and immune system, mainly bone marrow suppression, significantly increases the risk of anemia and bleeding, and decreases immune function, leading to an increase in complications and seriously affecting the patient's quality of life.

Currently, for ionizing radiation damage, Western medicine mostly uses high-dose antibiotics and glucocorticoids, as well as chemically synthesized substances such as cysteamine, amifostine, and estradiol. The efficacy is not ideal, and the side effects are high, so it cannot be used for a long time. In recent years, many scholars have found that traditional Chinese medicine can improve the quality of life of radiotherapy patients, prolong survival, and have a good protective effect on damage caused by radiotherapy. The combination of various traditional Chinese medicines can regulate spleen and stomach deficiency caused by radiotherapy and effectively prevent bone marrow suppression. According to reports, the traditional Chinese medicine Shiquan Dabu Decoction (composition of Chinese medicine: Angelica sinensis, Chuanxiong rhizome, white peony root, Rehmannia glutinosa, ginseng, Atractylodes macrocephala, Poria cocos, licorice root, astragalus, cinnamon), Bazhen decoction (composition of Chinese medicine: ginseng, Atractylodes macrocephala, white Poria cocos) , Angelica sinensis, Ligusticum chuanxiong, white peony root, Rehmannia glutinosa, licorice root), Yangzheng mixture (prescription composition: red ginseng, astragalus, wolfberry, Ligustrum lucidum, Polyporus, Poria), Buzhong Yiqi decoction (prescription composition: astragalus , Zhigancao, ginseng, angelica, orange peel, cohosh, bupleurum, and atractylodes), Danggui Buxue Decoction (prescription: astragalus, angelica), Liuwei Dihuang Pills (prescription: Rehmannia glutinosa, cornus, peony bark, yam) , Poria cocos, Alisma), etc., have a good effect on improving and preventing damage to the blood, genetics, immunity, antioxidant system and other damage caused by radiation. Some ingredients in traditional Chinese medicine, such as polysaccharides, alkaloids, saponins, volatile oils, coumarins, etc., can play a role in scavenging free radicals, promoting granulocyte hematopoiesis, increasing white blood cells, enhancing the body's immunity, and repairing damage to hematopoietic tissue.

From the perspective of traditional Chinese medicine etiology, ionizing radiation will invade the human body through the fur, mouth, nose, and orifices, damage the organs, cause organ dysfunction, and imbalance of qi, blood, yin and yang. The pathological evolution process induced is consistent with the pathogenic characteristics of toxins. , so it can be regarded as an external poisonous evil. At the same time, ionizing radiation has high energy, strong heat source and penetrating power. It releases a large amount of energy when it works, making the poisonous evil both fiery and hot. According to its action characteristics, it can be regarded as a fire poison and a heat poisonous evil. Fire, blood stasis, and deficiency are the basic pathogenesis. The main cause is "deficiency of fluid and blood, endogenous pathogenic heat, and deficiency of yin results in strong fire and unbearable dryness and heat." The recipe for Yinhuo Decoction comes from Chen Shiduo's "Syndrome Dialectical Record" of the Qing Dynasty. Its medicinal composition is: Rehmannia glutinosa, Morinda officinalis, Poria, Ophiopogon japonicus, and Northern Five Flavors. Yinhuo Decoction nourishes yin to reduce deficient fire, and yinhuo returns to its origin to coordinate yin and yang. It is suitable for cases of yin deficiency and excessive fire when yin fluid is deficient and yang heat is generated internally. The applicant initially discussed the mechanism of action of Yinhuo Tang in preventing and treating ionizing radiation damage [Zhou Lihui, et al. Based on network pharmacology to explore the mechanism of action of Yinhuo Tang in preventing and treating radioactive damage [J]. Specialty Products Research, 2022, 44(4): 44-52. ].

Contents of the invention

The present invention provides a pharmaceutical composition for reducing the harm of ionizing radiation. The purpose is to provide a pharmaceutical composition and medicine for reducing the damage caused by ionizing radiation with clear ingredients and better effects. The present invention conducts in-depth research on the Huohuo Decoction, searches for its relevant active ingredients, and develops a pharmaceutical composition with clear ingredients and better effects that can reduce ionizing radiation damage. The use of the pharmaceutical composition and its medicines can effectively help the body repair damage caused by ionizing radiation and promote the body's recovery as soon as possible; it can be used to reduce ionizing radiation damage and reduce the side effects of cancer radiotherapy.

The technical solution adopted by the present invention is: it consists of the following components by weight:

570-630 parts of Rehmannia glutinosa, 4-14 parts of Crystal Cyanoside, 17-27 parts of Nessin, 60-80 parts of Ophiopogon japonicus polysaccharide, 75-95 parts of Poria polysaccharide, 1-5 parts of Poria acid, and 1-3 parts of Schizandrin share.

The preparation method of the Ophiopogon japonicus polysaccharide is: crush Ophiopogon japonicus to obtain Ophiopogon japonicus powder with a particle size of 120-180 mesh, add water to soak: the mass volume ratio of Ophiopogon japonicus powder to water is 1:8-16, g/mL, soaking time 0.5-2h, decoct and extract, the decoction temperature is 90-100°C, decoct 2-4 times, each decoction time is 0.5-2h, separate the filtrate, concentrate and dry to obtain Ophiopogon japonicus polysaccharide.

The drying is any one of conventional drying: freeze drying, vacuum drying, spray drying, boiling drying or microwave drying.

A preparation method of a pharmaceutical composition for reducing the hazards of ionizing radiation, including the following steps:

(1) Crush Rehmannia glutinosa to obtain Rehmannia glutinosa powder, add water to soak, decoct and extract, separate the filtrate, concentrate and dry to obtain Rehmannia glutinosa extract;

(2) Mix the Rehmannia glutinosa extract with the remaining composition components crystalline glycoside, Nessose, Ophiopogon japonicus polysaccharide, Poria polysaccharide, Poria acid, and Schisandrin to obtain a pharmaceutical composition.

In the step (1), the particle size of the cooked rehmannia glutinosa powder is passed through a 5-20 mesh sieve, and the material-to-liquid mass volume ratio with water is 1:8-20, g/mL; after the cooked rehmannia glutinosa powder is mixed with water, soak for 0.5-2h , decoct and extract 2-4 times, 1-2 hours each time, filter the extract, combine the filtrate, concentrate and dry the filtrate to obtain the Rehmannia glutinosa extract.

Application of a pharmaceutical composition for reducing the harm of ionizing radiation in preparing medicine for reducing the harm of ionizing radiation.

A pharmaceutical composition for reducing the harm of ionizing radiation includes the pharmaceutical composition and medically acceptable excipients; the dosage form of the pharmaceutical is any pharmaceutically acceptable dosage form: pills, tablets, capsules, granules, mixtures or any of the oral solutions.

The medically acceptable excipients include starch, dextrin, sucrose, milk powder, sweeteners, mannitol, lactose, cellulose and its derivatives, calcium carbonate, cyclodextrin, β-cyclodextrin , phospholipid materials, magnesium stearate, talc, preservatives or flavors.

The beneficial effects of the present invention are:

1. On the basis of the recipe of Yinhuo Decoction, the present invention screened the traditional Chinese medicine ingredients and active ingredients of the prescription, and obtained the present invention containing Rehmannia glutinosa, Crystal Cyanoside, Naisose, Ophiopogon japonicus polysaccharide, Poria polysaccharide, and Poria acid. , Schisandrin composition, each active ingredient cooperates with each other to help the body repair damage caused by ionizing radiation, promote the recovery of the damaged hematopoietic system and immune system, increase the number of peripheral blood white blood cells and reduce the number of bone marrow cell micronuclei. The pharmaceutical composition and its preparations can effectively prevent and reduce the harm of ionizing radiation, and are beneficial to reducing the side effects of cancer radiotherapy.

2. The present invention selects the main active ingredients from various medicinal materials, combines them reasonably, and works synergistically to effectively repair body damage caused by ionizing radiation; the raw materials of the composition are prepared by optimizing the extraction method, and the extraction rate of active ingredients is high, making full use of them. Medicinal material resources; using specific methods to prepare pharmaceutical compositions, the composition has clear ingredients, which can ensure stable and controllable quality and stable efficacy, which is conducive to popularization and application. It can be used to reduce side effects for tumor patients undergoing radiotherapy and reduce ionizing radiation damage from various sources. .

Detailed ways

In order to further clarify the features of the present invention, the following is further described in conjunction with specific embodiments. It should be noted that the following embodiments are only preferred embodiments of the present invention, not all of them. Based on the following examples, those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, which should also fall within the scope of protection claimed by the present invention. In the following examples, unless otherwise specified, the operating methods used are conventional operating methods, the equipment used are conventional equipment, the equipment materials used in each embodiment are the same, and the preparation method is conventional mixing. In the following examples, all raw materials used are commercially available products, and all water used is pure water.

The following non-limiting examples can enable those of ordinary skill in the art to understand the present invention more comprehensively, but do not limit the present invention in any way. The following content is only an illustrative description of the scope of protection claimed by the present invention. Those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, which should also fall within the scope of protection claimed by the present invention.

When the examples give numerical ranges, it should be understood that, unless otherwise stated in the present invention, both endpoints of each numerical range and any value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

The present invention will be further described below in the form of specific examples. Unless otherwise specified, various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels. In the following examples and comparative examples, the crystalline cyanoside (molecular formula C ₁₆ H ₂₂ O ₁₁ , CAS No: 5945-50-6), nesose (molecular formula C ₂₄ H ₄₂ O ₂₁ , CAS No: 13133- 07-8), Poria polysaccharide (CAS No: 65673-98-1), Poria acid (Molecular formula C ₃₃ H ₅₂ O ₅ , CAS No: 29070-92-6), Schisandrin (Molecular formula C ₂₄ H ₃₂ O ₇ , CAS No: 7432-28-2), the Rehmannia glutinosa is the dried root tuber of Scrophulariaceae plant Rehmannia glutinosa, processed products according to the processing method stipulated in the "Chinese Pharmacopoeia". The specific processing method has no impact on the technical effect. If there is no special Note that the Rehmannia glutinosa used in the examples and comparative examples is a commercially available product. Described Ophiopogon japonicus is the dried root tuber of Liliaceae plant Ophiopogon japonicus. Ophiopogon japonicus nourishes yin and promotes fluid production, moistens the lungs and clears the heart. It is used for dry cough due to yin deficiency, tuberculosis cough caused by yin deficiency, sore throat, sore throat, thirst in body fluids, wounds, internal heat, quenching thirst, and upset. Insomnia, intestinal dryness and constipation.

In the following examples, the preparation method of the Ophiopogon japonicus polysaccharide is: crush Ophiopogon japonicus, pass through a 120-mesh sieve to obtain Ophiopogon japonicus powder, mix with 15 times the amount of water, soak for 1 hour, decoct at 95-100°C, and decoct Decoction three times for 1 hour each time to extract active substances, separate the filtrate, concentrate and dry to obtain Ophiopogon japonicus polysaccharide.

Examples 1-5

A pharmaceutical composition for reducing the hazards of ionizing radiation, including components as shown in Table 1 in parts by weight:

Table 1 Components and their weight parts in Examples 1-5

parts by weight Example 1 Example 2 Example 3 Example 4 Example 5 Rehmannia glutinosa 600 570 630 600 600 Crystal Cyanoside 9 4 14 11 7 Nice sugar twenty two 17 27 26 18 Ophiopogon japonicus polysaccharide 70 60 80 70 70 Poria polysaccharide 85 75 95 80 90 Poria acid 3 1 5 2.4 3.6 Schisandrin 2 1 3 2 2

The preparation method of the pharmaceutical composition of Examples 1-5 includes the steps:

(1) Crush Rehmannia glutinosa to obtain Rehmannia glutinosa powder, pass through a 20-mesh sieve, mix with water, the volume ratio of Rehmannia glutinosa powder to water is 1:12, soak for 1 hour, boil and extract 3 times, 1.5 hours each time, filter the extract and combine The filtrate is concentrated and dried to obtain Rehmannia glutinosa extract;

(2) Mix the Rehmannia glutinosa extract with the remaining composition components crystalline glycoside, Nessose, Ophiopogon japonicus polysaccharide, Poria polysaccharide, Poria acid, and Schisandrin to obtain a pharmaceutical composition.

Control extract: Prepare the control extract according to the original recipe of Yinhuo Decoction (three liang of Rehmannia glutinosa, one liang of Morinda officinalis and Ophiopogon japonicus, two qian of Beiwei, and five qian of Poria cocos), and include the following ingredients in parts by weight: 600 parts of Rehmannia glutinosa, 200 parts of Morinda citrifolia, Ophiopogon japonicus 200, Beiwei 40, Poria 100. Crush the above medicinal materials to obtain medicinal powder, pass through a 20 mesh sieve, mix with water, the volume ratio of medicinal powder to water is 1:12, soak for 1 hour, decoct and extract 3 times, 1.5 hours each time, filter the extract, combine the filtrate, and concentrate , dried to obtain the control extract.

Comparative Example 1: The pharmaceutical composition includes the following ingredients in parts by weight: 600 parts of Rehmannia glutinosa extract, 9 parts of astragaloside, 22 parts of naiseose, 70 parts of Ophiopogon japonicus polysaccharide, 85 parts of Poria polysaccharide, and 3 parts of Poria acid. , 2 parts of Schisandrin.

The preparation method of the above pharmaceutical composition is the same as in Example 1.

The difference from Example 1 is that the components of the pharmaceutical composition have been changed, and the crystalline cyanide in the pharmaceutical composition has been replaced by astragaloside. The remaining components, weight parts, and preparation methods of the pharmaceutical composition are the same as those in Example 1. .

Comparative Example 2: The pharmaceutical composition includes the following ingredients in parts by weight: 600 parts of Rehmannia glutinosa extract, 9 parts of crystalline cyanide, 22 parts of sucrose, 70 parts of fructose, 85 parts of Poria polysaccharide, 3 parts of Poria acid, Schisandra chinensis 2 servings of vegetarian food. The preparation method of the above pharmaceutical composition is the same as in Example 1.

The difference from Example 1 is that the components of the pharmaceutical composition were changed, and the nesose, Ophiopogon japonicus polysaccharide and Poria polysaccharide in the pharmaceutical composition were replaced by sucrose, fructose and Poria polysaccharide. The remaining components, weight parts and preparation method of the pharmaceutical composition are the same as in Example 1.

Comparative Example 3: The pharmaceutical composition includes the following ingredients in parts by weight: 600 parts of Rehmannia glutinosa extract, 9 parts of Crystal Cyanoside, 22 parts of Nessaccharide, 70 parts of Ophiopogon japonicus polysaccharide, 85 parts of Poria Polysaccharide, and ferulic acid 3 parts, 2 parts Schisandrin.

The difference from Example 1 is that the components of the pharmaceutical composition were changed, and the poria acid in the pharmaceutical composition was replaced by ferulic acid. The remaining components, weight parts and preparation method of the pharmaceutical composition are the same as in Example 1.

Comparative Example 4: The pharmaceutical composition includes the following ingredients in parts by weight: 600 parts of Rehmannia glutinosa extract, 9 parts of crystalline cyanide, 22 parts of naisin, 70 parts of Ophiopogon japonicus polysaccharide, 85 parts of Poria polysaccharide, and 3 parts of Poria acid 2 parts of citric acid.

The difference from Example 1 is that the components of the pharmaceutical composition were changed, and the schisandrin in the pharmaceutical composition was replaced by citric acid. The remaining components, weight parts and preparation method of the pharmaceutical composition are the same as in Example 1.

Efficacy evaluation test

The present invention conducts an efficacy evaluation test of a pharmaceutical composition in reducing the harm of ionizing radiation, observes the effect of the pharmaceutical composition of the present invention on model animals damaged by ionizing radiation, and evaluates its effect in reducing the harm of ionizing radiation.

experimental method

Preparation methods of pharmaceutical compositions and control extracts of Examples 1-5 and Comparative Examples 1-4:

1. Mix the compositions of Examples 1-5 and Comparative Examples 1-4 according to the weight parts of each component of Examples 1-5 and Comparative Examples 1-4 in Table 1 to prepare a powder. Prepare the control extract according to the preparation method of the control extract and make it into powder. Before use, disperse the powder with an equal amount of distilled water, shake well before use, and store at 4°C. The compositions of Examples 1-5, Comparative Examples 1-4, and the control extract were evaluated for their protective effects against ionizing radiation damage.

2. Experimental animals: Kunming healthy SPF grade female mice, weighing 18g to 22g, were selected.

3. Dosing Method: The pharmaceutical compositions and control extracts of Examples 1-5, Comparative Examples 1-4, are administered at a dose of 1.2g/kg. It was administered orally once a day, and after continuous gavage for 28 days, irradiation was performed, and then the test substance was continued to be administered until the end of the experiment. The intragastric volume of mice was 10 mL/kg BW. At the same time, the model control group (0mL/kgBW) used sterile water instead of the test substance, and the daily gavage volume was the same as that of each test substance group. Each group was given maintenance feed.

4. Evaluate pilot projects

4.1 Peripheral blood leukocyte count experiment: The test sample group was continuously administered the test sample orally before and after irradiation. Both the dose group and the model control group were irradiated once with the same dose of γ-rays, and the irradiation dose was selected to be 3.0Gy (absorbed dose rate 1.0 Gy/60s, time 3min). Collect 20 μL of peripheral blood three times before irradiation, on the 3rd day after irradiation, and on the 14th day after irradiation. Add 0.38 mL of 1% hydrochloric acid. After mixing, add it to a hemocytometer counting board. Calculate the total number of white blood cells in the four large squares in the counting cell. .

4.2 Mouse bone marrow cell micronucleus experiment: The dose group was continuously orally administered test samples before and after irradiation. The dose group and the radiation model control group were all irradiated once with the same dose of γ-rays. The irradiation dose was selected to be 3.0Gy (absorbed dose rate 1.0 Gy/60s, time 3min). On the 3rd day after irradiation, the animals were killed by cervical dislocation, the sternum was removed, the bone marrow fluid was squeezed out with a hemostat and mixed with calf serum at one end of the slide, and a routine smear was performed. After the smear was naturally dried, it was fixed in methanol for 10 min, placed in Giemsa applied dye solution, stained for 15 min, rinsed immediately with distilled water, and dried. For microscopic examination, the number of micronucleated cells in 1,000 polychromatic erythrocytes per animal was counted, and the micronucleus rate was expressed in parts per thousand.

5. Statistical analysis

The statistical software SPSS29.0 was used to perform statistical analysis and processing on the experimental data of various indicators. The data results were expressed as mean ± standard deviation. Indicates that the one-way analysis of variance (ANOVA) was used for comparison between groups, and the LSD method was used for pairwise comparison. P<0.05 was considered as a statistically significant difference.

2. Results

1. The experimental results of peripheral blood leukocyte count are shown in Table 2:

Table 2 Effects on the number of peripheral blood leukocytes in mice irradiated with X-rays (n=10, )

Note: Compared with the blank group, ^* : p<0.05, ^** : p<0.01; compared with the model group, ^# : p<0.05, ^## : p<0.01; compared with Example 1, ★: p< 0.05, ★★: p<0.01; compared with Example 2, ※: p<0.05, ※※: p<0.01; compared with Example 3, ☆: p<0.05, ☆☆: p<0.01; compared with Example 4 Compared with, ◇: p<0.05, ◇◇: p<0.01; compared with Example 5, ◆: p<0.05, ◆◆: p<0.01

2. The results of mouse bone marrow cell micronucleus experiment are shown in Table 3:

Table 3 Effects on micronucleus rate of bone marrow cells in mice irradiated with X-rays (n=10, )

Note: Compared with the blank group, ^* : p<0.05, ^** : p<0.01; compared with the model group, ^# : p<0.05, ^## : p<0.01;

Compared with Example 1, ★: p<0.05, ★★: p<0.01; Compared with Example 2, ※: p<0.05, ※※: p<0.01; Compared with Example 3, ☆: p<0.05, ☆☆: p<0.01; compared with Example 4, ◇: p<0.05, ◇◇: p<0.01; compared with Example 5, ◆: p<0.05, ◆◆: p<0.01

3. Conclusion

In Comparative Examples 1-4, the components in the composition were replaced with other components in sequence. Since Astragalus has a good protective effect on damage caused by radiotherapy, in Comparative Example 1, astragaloside, the main active ingredient in Astragalus, was used to replace Crystal Cyanoside in Morinda officinalis. The experimental results show that the effect of Comparative Example 1 is not as good as that of the Example, but the effect is equivalent to that of the Comparative Example. Because naisitose is sucrose, and the monosaccharides of Ophiopogon japonicus polysaccharide are mainly fructose and glucose, so in Comparative Example 2, fructose and sucrose were used to replace naisitose and Ophiopogon japonicus polysaccharide, and Poria polysaccharide, which is also an ingredient in Poria cocos, was used. Sugar replaces Poria cocos polysaccharide. The experimental results show that the effect of Comparative Example 2 is not as good as that of the Example, but the effect is equivalent to that of the Comparative Example. Angelica sinensis has a blood-tonifying effect and is also an important component of traditional Chinese medicines such as Shiquan Dabu Decoction and Bazhen Decoction for radiotherapy. Ferulic acid is an index component of Angelica sinensis. In Comparative Example 3, ferulic acid was used to replace poria acid. The experimental results show that the effect of Comparative Example 3 is not as good as that of the Example, but the effect is equivalent to that of the Comparative Example. The active compounds in Schisandra chinensis mainly include two types of components, one is lignin compounds (schisandrin, etc.), and the other is organic acids (mainly citric acid, malic acid, etc.). Therefore, in Comparative Example 4, citric acid was used instead of schizandrin. The experimental results show that the effect of Comparative Example 4 is not as good as that of the Example, but is equivalent to the effect of the Comparative Example. Generally speaking, the effect of the embodiment is better than that of the control extract and the comparative example prepared according to the recipe of Yinhuo Decoction, and the effect of the comparative example and the control extract is equivalent. The effects of Comparative Examples 1-4 on reducing body damage in irradiated mice were all lower than those of the Examples, indicating that each component in the pharmaceutical composition of the present invention is the best choice.

The pharmaceutical composition of the present invention has the effect of reducing the harm of ionizing radiation; it can effectively promote the recovery of the blood system, increase the number of peripheral blood leukocytes of irradiated mice, reduce the number of micronuclei of bone marrow cells, and reduce damage to the body's chromosomes. The pharmaceutical composition of the present invention has clear ingredients, reasonable compatibility and optimal curative effect.

Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, but does not limit the protection scope of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by those of ordinary skill in the art do not deviate from the scope of the present invention. The essence and scope of the technical solution of the invention.

Claims (8)

1. A pharmaceutical composition for mitigating the harm of ionizing radiation, characterized in that it consists of the following components by weight: 570-630 parts of Rehmannia glutinosa, 4-14 parts of Crystal Cyanoside, 17-27 parts of Nessaccharide, and Ophiopogon japonicus polysaccharide. 60-80 parts, 75-95 parts of Poria polysaccharide, 1-5 parts of Poria acid, and 1-3 parts of Schisandrin. 2. A pharmaceutical composition for mitigating the harm of ionizing radiation according to claim 1, characterized in that the preparation method of the Ophiopogon japonicus polysaccharide is: crush Ophiopogon japonicus to obtain Ophiopogon japonicus powder with a particle size of 120-180 mesh, add water Soaking: The mass-to-volume ratio of Ophiopogon japonicus powder and water is 1:8-16, g/mL, the soaking time is 0.5-2h, and decoction is extracted. The decoction temperature is 90-100°C, and the decoction is 2-4 times, each decoction time is 0.5-2h, the filtrate is separated, concentrated and dried to obtain Ophiopogon japonicus polysaccharide. 3. A pharmaceutical composition for mitigating the harm of ionizing radiation according to claim 2, characterized in that the drying is any one of conventional drying: freeze drying, vacuum drying, spray drying, boiling drying or microwave drying. kind. 4. The preparation method of the pharmaceutical composition according to any one of claims 1-3, characterized in that it includes the following steps: (1) Crush Rehmannia glutinosa to obtain Rehmannia glutinosa powder, add water to soak, decoct and extract, separate the filtrate, concentrate and dry to obtain Rehmannia glutinosa extract; (2) Mix the Rehmannia glutinosa extract with the remaining composition components crystalline glycoside, Nessose, Ophiopogon japonicus polysaccharide, Poria polysaccharide, Poria acid, and Schisandrin to obtain a pharmaceutical composition. 5. The preparation method according to claim 4, characterized in that in the step (1), the particle size of the cooked rehmannia glutinosa powder is passed through a 5-20 mesh sieve, and the material liquid mass volume ratio with water is 1:8-20 , g/mL; after mixing the Rehmannia glutinosa powder with water, soak it for 0.5-2h, boil and extract it 2-4 times, 1-2h each time, filter the extract, combine the filtrate, and concentrate and dry the filtrate to obtain the Rehmannia glutinosa extract. 6. Application of the pharmaceutical composition according to any one of claims 1 to 3 in the preparation of drugs for reducing the harm of ionizing radiation. 7. A medicine, characterized in that: the active ingredient includes the pharmaceutical composition according to any one of claims 1-3. 8. The medicine according to claim 7, characterized in that: it includes the pharmaceutical composition and medically acceptable excipients; the dosage form of the medicine is any pharmaceutically acceptable dosage form: pills, tablets, capsules , granules, mixtures or oral liquids.